After market hours on Thursday, shares of Conformis Inc. (NASDAQ: CFMS) rose 10.47% to $0.95. Conformis closed the regular trading session at $0.86, up 6.12%. The price range on the day was between $0.8105 and $0.8866 for the CFMS stock.
Conformis stock has traded 1.81 million shares, down from its average daily volume of 4.57 million shares. Last five days, CFMS stock has gained 3.74% but last month, -20.37%. Regular and extended trading saw CFMS stock rise following FDA approval of its instrument.
When it comes to discovering hidden gems within the stock market, Stock Wire News has consistently provided invaluable insights. Stock Wire News invites you to explore their upcoming Wealth Building Report. This report will shine a spotlight on little-known companies with the potential for substantial growth in 2024, and it's completely FREE for a limited time.
Claim the free report now by clicking here and start discovering the hidden gems of the market
Sponsored
Read More
What was the approval for?
In the healthcare industry, Conformis develops, manufactures, and sells joint replacement implants and instruments using its proprietary iFit Image-to-Implant technology platform. A wide range of sterile fully-customized knee replacements and hip replacements, as well as single-use instruments, are available to hospitals and outpatient surgical centers offered by CFMS.
Yesterday, Conformis announced that the FDA granted 510(k) clearance for CFMS-developed patient-specific instrumentation (PSI).
- This PSI device was part of CFMS’s License Agreement and Development Agreement with Howmedica Osteonics Corp., wholly owned by Stryker Corporation.
- The PSI System, created by CFMS, is intended to be used with the Triathlon Total Knee System developed by Stryker.
- The clearance also brings CFMS to milestone 3 of the agreements and it will now become eligible to receive $11.0 million from Stryker.
Further plans:
Conformis (CFMS) is now focused on its long-term distribution agreement with Stryker to manufacture and supply PSI system. As demand grows for efficient outpatient ambulatory surgery center joint replacement, CFMS continues to believe this initiative will create shareholder value.
